Clinical Trial Update: IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma [NA]

View source ↗

Summary

Clinical trial investigating IFN-gamma expression as a predictor of response to immune checkpoint inhibitors in first-line metastatic melanoma; the study is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: Institute of Oncology Ljubljana | Conditions: Metastatic Melanoma, Malignant Melanoma | NA | Status: COMPLETED